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90% of the dose was cleared within 2 min for an instilled 
volume of 50 µl.[4] Consequently, the ocular residence time 
of conventional solution is limited to few minutes, and the 
overall absorption of a topically applied drug is limited 
to 1-10%.[5] Consequently, most drugs get systemically 
absorbed via the nose or gut after draining from eye. This 
excessive systemic absorption not only reduces the ocular 
bioavailability, but also may lead to unwanted side effects 
and toxicity.
To increase ocular bioavailability and duration of the 
drug action, various ophthalmic vehicles, such as viscous 
solutions, ointments, gels, or polymeric inserts, have been 
INTRODUCTION
One of the main problems encountered in ophthalmic 
drug delivery is the rapid and extensive elimination of 
conventional eye drops from the eye. This process results 
in extensive drug loss. Consequently, only a small amount 
(1-6%) actually penetrates the cornea and reaches the 
intra ocular tissues.[1,2] The reasons for this inefﬁ  cient drug 
delivery includes rapid tear turnover, lachrymal drainage, 
and drug dilution by tears.[3] The higher drainage rate is due 
to tendency of the eye to maintain its residence volume at 
7-10 µl permanently, whereas volumes of topically instilled 
range from 20 to 50µl. It has been demonstrated in vivo that 
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ABSTRACT
The present work describes the formulation development of ophthalmic in situ gelling system using thermo-
reversible gelling polymer, i.e. Pluronic F 127 (PF127). Because of high concentration (20 to 25%w/v) of this 
polymer required for in situ gelation causes irritation to the eye. So, to reduce this concentration, an attempt was 
made to combine the PF127 with other polymers like hydroxy propyl methyl cellulose (HPMC) as a viscosity 
increasing agent or with polymers like carbopol 940, xanthan gum, and sodium alginate (high glucuronic acid 
content) showing a pH and cation-triggered sol-gel transition, respectively. Different batches were prepared of 
varying concentrations of these polymers with PF127 using cromolyn sodium 2%w/v in phosphate buffer pH 5.0. 
The formulations were optimized by the viscosity measurement and in vitro gelation study. Selected formulations 
were evaluated for in vitro drug release proﬁ  le and indicated sustain drug release over a period of 10 h. Effect 
of sterilization on drug content, pH, clarity, and viscosity were also evaluated. Finally, we concluded that by 
using this type of combination system, we could reduce not only the concentration of individual polymers but 
also the side effects without compromising the in vitro gelling capacity as well as overall rheology of the system.  
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used.[6] The corneal contact time has been increased to 
varying degrees by these vehicles, but because of blurred 
vision (i.e. ointments) or lack of patient compliance (i.e. 
inserts), they have not been widely accepted.
From the point of view of patient acceptability, a liquid 
dosage form that can sustain drug release and remain in 
contact with the cornea of the eye for extended periods 
of time is ideal. If the precorneal residence time of a drug 
could be improved from 5 min to say a few hours, then 
improved local bioavailability, reduced dose concentrations 
and dosing frequency, and improved patient acceptability 
may be achieved. Drug delivery systems based on the 
concept of in situ gel formation should provide these 
properties. Such delivery systems consist of phase 
transition polymers that are instilled in a liquid form and 
shift to the gel phase once in the cul-de-sac of the eye. 
Several polymers, demonstrating phase transition due to 
changes in their microenvironment, were investigated. 
Among them are poloxamer 407[7] and tetronics,[8] as well 
as ethyl (hydroxyethyl) cellulose,[9] whose solution viscosity 
increases upon increasing the temperature to that of the 
eye, cellulose acetophthalate (CAP) latex,[10] that coagulates 
when its native pH of 4.5 is raised by the tear ﬂ  uid to pH 7.4 
and GelriteTM, a polysaccharide which gels in the presence 
of mono or divalent cations.[11] However, most of these 
vehicles are characterized by a high polymer concentration 
(25% poloxamer, 30% CAP) which is not well tolerated 
by the eye.
The present study demonstrate that a reduction in pluronic 
concentration, without compromising the in situ gelling 
capabilities as well as overall rheological properties of 
the delivery system, can be achieved by addition of inert 
polymer acting as viscosity enhancer like HPMC or polymer 
that shows in situ sol-gel transition via another mechanism 
with desired rheological properties and ability to deliver the 
drug in sustained manner. 
MATERIALS AND METHODS
Materials
PF127 obtained from BASF India Ltd, sodium alginate 
(Manugel DMB) from M. S. Uni., Baroda, Xanthangum 
obtained from Glasston Ltd, Bhavnagar, Carbopol 940 
from Corel Pharma, Ahmedabad, HPMC (Hydroxy propyl 
methyl cellulose) obtained from Colorcon India Ltd, PVA 
(Polyvinyl alcohol) and cromolyn sodium were obtained 
from Indiana Ophthalmic, Bhavnagar. Other ingredients 
used were of analytical grade and include citric acid, 
sodium dihydrogen phosphate, sodium chloride, sodium 
bicarbonate, benzalkonium chloride, disodium editate, 
calcium chloride, and sterile distilled water.
Methods
Preparation of  in situ gel formulation
First of all the aqueous dispersions of the selected 
concentrations of Carbomer 940 (0.3%, 0.4%, and 0.5%) 
respectively for batches (C1, C2, and C3) and Sodium 
Alginate (0.3, 0.4, 0.5%, 0.7%, 0.9%, and 1.5%) respectively 
for batches (S1, S2, S3, S4, S5, and S6) and Xanthan gum 
(0.3%, 0.4%, 0.5%) respectively for batches (X1, X2, and 
X3) in citro phosphate buffer pH 5.0 were prepared for 
the control batches and for the further study. Similarly, for 
preparation of pluronic dispersions, varying concentrations 
of PF127 (10%, 12%, 14%, 15%, and 16%) respectively 
for batches (P1, P2, P3, P4, P5) were dispersed in the 
buffer solution with continuous stirring for 5 min. The 
partially dissolved pluronic solutions were stored in the 
refrigerator until the entire polymer was completely 
dissolved (approximately 24 h). Similarly, the batches for 
pluronic/carbopol (batches CP1 to CP15) and pluronic/
alginate (batches SP1 to SP11) and pluronic/Xanthan 
gum (batches XP1 to XP5) solutions were prepared by 
dispersing the pluronic in the desired concentrations 
of respective polymer solutions. The partially dissolved 
solutions were then refrigerated until thoroughly mixed 
(approximately 24 hrs). All the previous sample solutions 
were adjusted to pH 5.0±0.1 with 0.5 M hydrochloric 
acid solution and then stored in the refrigerator before 
evaluation of their properties under non-physiological 
conditions (pH 5.0 and 25°C).[10] The same procedure 
was used to prepare the dispersions for characterization 
under physiological conditions (pH 7.4 and 37 °C); 
the simulated tear ﬂ  uid (NaCl 0.67 g, NaHCO3 0.20 g, 
CaCl2*2H2O 0.008 g, and distilled deionized water to 100 
g), however, was used as a dispersion medium instead. 
The prepared solutions were adjusted to pH 7.4±0.1 with 
0.5 M sodium hydroxide solution and then stored in the 
refrigerator before evaluation of their properties under 
physiological conditions. In the prepared batches 2%w/v 
cromolyn sodium and other adjuvants were incorporated. 
The detailed procedure for the preparation of in situ gel 
forming system is as follows.
The buffer salts were dissolved in about 70 ml of sterile 
distilled deionized water. Then polymers were sprinkled and 
allowed to hydrate overnight. The drug cromolyn sodium 
was dissolved in another 20 ml of sterile distilled water 
and required quantities of disodium editate as chelating 
agent and sodium chloride as osmogen were incorporated. 
Benzalkonium chloride was then added as a preservative. 
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The drug solution was ﬁ  nally added to polymer solution 
with constant stirring. The pH of the system was adjusted 
to 5.0±0.1 with 0.5 M NaOH solution. Final volume was 
adjusted with distilled water.
All formulations were prepared in citro phosphate buffer 
pH 5.0 were stored in the refrigerator and the rheological 
proﬁ  les of each solution were measured at 12 rpm for 
comparative evaluation study using Brook ﬁ  eld viscometer 
at 25ºC and at 37ºC.
Viscosity and in vitro gelling efﬁ  ciency 
The prepared formulations were evaluated for in vitro 
gelling efﬁ  ciency and viscosity in order to identify the 
compositions that best suit for the use as in situ gelling 
systems [Table 1]. The in vitro gelling efficiency was 
determined by placing a drop of the system in a test-tube 
containing 2 ml of simulated tear ﬂ  uid (STF) freshly 
prepared and equilibrated at 37 °C. The visual assessment 
of gel formation was carried out simultaneously the time 
required for gelation as well as time taken for the formed 
gel to dissolve was also noted. The viscosity of the systems 
was measured using Brookﬁ  eld viscometer (LVT model) 
at 12 rpm for the purposes of comparative evaluation. 
The ﬂ  ow behavior of vehicles was determined by various 
signs obtained by visual inspection. The ﬂ  ow behavior 
with the “+” sign indicates the vehicle is in the liquid form 
and is very easy to ﬂ  ow which shows mild gelation after a 
few minutes and the gel dissolves rapidly. The “++” sign 
indicates that the vehicle is in the liquid-gel like form and 
ﬂ  ows less readily, which shows gelation immediate the 
gel remains for <1 h. The ﬂ  ow behavior with the “+++” 
sign indicates that the sample is in the gel form and is very 
difﬁ  cult to ﬂ  ow which also shows immediate gelation and 
the gel remains for the extended period of time. The ﬂ  ow 
behavior with the “++++” sign indicates that the vehicle 
is a strong gel and cannot ﬂ  ow at 25°C and 5.0 pH.
Rheological study
The selected formulations (pH 5.0) at 25°C were poured 
into the sample adaptor of the Brookﬁ  eld viscometer (LVT 
model) and the angular velocity was increased gradually 
from 0.3 to 30 rpm. The hierarchy of the angular velocity 
was reversed and average dial reading was considered 
to calculate the viscosity. Same formulations were again 
evaluated for viscosity in a similar fashion after adjusting 
their temperature to 37 °C and pH to 7.4 by adding 0.5M 
NaOH. The temperature was maintained within ±1.0 
°C by a recirculating bath connected to the sample cup 
of the viscometer. The samples were equilibrated on the 
plate for 5 min to reach the running temperature before 
each measurement. The viscosity measured at both the 
conditions for selected formulations were plotted versus 
the angular velocity (rpm). Comparative rheological proﬁ  les 
were shown for all three formulations together in Figures 
1 and 2. All the measurements were taken in triplicate. 
In vitro drug release study
The in vitro release pattern of cromolyn sodium was 
studied using modiﬁ  ed dissolution test apparatus.[12,13] 
Freshly prepared simulated tear ﬂ  uid (pH 7.4) was used as 
dissolution medium. Cellophane membrane, previously 
soaked overnight in the dissolution medium, was tied to 
one end of a specially designed glass cylinder (open at both 
ends and of 3 cm diameter). 2 ml of the formulation was 
accurately pipetted into the cylinder and was suspended 
in 500 ml of dissolution medium maintained at 37 ±1°C 
in such a way that the membrane just touched the surface 
of the receptor medium. The dissolution medium was 
magnetically stirred at 100 rpm. 10 ml aliquots were 
withdrawn every hour replacing equal volume of the 
fresh dissolution medium and were analyzed directly by 
UV spectrophotometer at 326 nm (Hitachi U-2000). All 
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Table 1: Viscosity and in vitro gelling capacity of 
prepared formulations
Formulation code Concentration (%w/v) Gelling capacity*
CP1 10 0.3 -- -- +
CP2 12 0.3 -- -- +
CP3 14 0.3 -- -- +
CP4 15 0.3 -- -- ++
CP5 16 0.3 -- -- ++
CP6 10 0.4 -- -- ++
CP7 12 0.4 -- -- ++
CP8 14 0.4 -- -- ++
CP9 15 0.4 -- -- +++
CP10 16 0.4 -- -- ++++
CP11 10 0.5 -- -- ++
CP12 12 0.5 -- -- ++
CP13 14 0.5 -- -- +++
CP14 15 0.5 -- -- ++++
CP15 16 0.5 -- -- ++++
XP1 10 -- 0.5 -- +
XP2 12 -- 0.5 -- ++
XP3 14 -- 0.5 -- ++
XP4 15 -- 0.5 -- +++
XP5 16 -- 0.5 -- ++++
SP1 14 -- -- 0.3 +
SP2 15 -- -- 0.3 +
SP3 14 -- -- 0.4 +
SP4 15 -- -- 0.4 ++
SP5 14 -- -- 0.5 +
SP6 15 -- -- 0.5 ++
SP7 14 0.7 ++
SP8 15 0.7 +++
SP9 14 -- -- 0.9 ++
SP10 15 -- -- 0.9 +++
SP11 15 1.5 ++++
*+ Mild gelation after a few minutes, gel dissolves rapidly
++    Gelation immediate, remains for <1 hr.
+++ - Gelation immediate remains for extended period. - +++ selected 
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Figure 2: Comparative rheological proﬁ  le of the selected formulations 
at pH 7.4 and 37°C
Figure 3: Comparative rheological proﬁ  le of the selected formulations 
at pH 7.4 and 37°C
the selected formulations (CP9, XP4, SP8 and SP10) were 
evaluated for the drug release pattern and were compared 
with the release pattern of control batches of PF127 
25% (P6) and 15% (P4), carbomer (C2), xanthan gum 
(X1), sodium alginate (S4 and S5). Also, the drug release 
proﬁ  le of the marketed eye drops (Cromal eye drops - 
Cipla) was compared with the same obtained with selected 
formulations as shown in Figure 3.
Effect of  sterilization
The selected formulations were ﬁ  lled in 10 ml capacity amber 
glass vials, closed with grey butyl rubber closures and sealed 
with aluminum caps. The vials were subjected to terminal 
sterilization by autoclaving at 121 °C and 15 psi for 20 min. 
The formulations were evaluated for drug content, viscosity, 
clarity, and pH before and after the terminal sterilization.
RESULTS AND DISCUSSION
Viscosity and in vitro gelling capacity
The two main prerequisites of an in situ gelling system are 
viscosity and gelling capacity. The formulation should have 
an optimum viscosity that will allow easy instillation into 
the eyes and would undergo a rapid sol-gel transition at 
the body temperature 37 °C and lachrymal pH 7.4. Also, 
the gel formed in situ should preserve its integrity without 
dissolving or eroding for a sufﬁ  cient period of time. 
Table 1 shows gelling efﬁ  ciency and viscosity of different 
formulations under study. Formulations coded as CP9, 
XP4, and SP10 (“_”Underline batches) were selected on the 
basis of their low viscosity with higher gelling capabilities 
and on the basis of clarity of the gel formed in the eye.
Rheological proﬁ  le
Remarkable increase in the viscosity was observed as 
the pH of the formulations was increased to 7.4 and 
temperature to 37 °C. Also, the formulations were found 
shear thinning, as decrease in viscosity was observed with 
an increase in angular velocity (pseudoplastic rheology). 
The administration of ophthalmic preparation should 
inﬂ  uence the pseudoplastic behavior of tear ﬁ  lm as little 
as possible.[14] The ocular shear rate is very large ranging 
from 0.03 S-1 during inter-blinking periods to 4250-28 550 
S-1 during blinking. So, viscoelastic ﬂ  uids with a viscosity 
that is high under the conditions of low shear rate and low 
under the conditions of high shear rate are preferred.[13] 
At pH 5.0 and temperature 25 °C, the formulations were 
in liquid state and exhibited low viscosity while at pH 
7.4 (lachrymal pH) and temperature 37 °C (physiological 
conditions), transformation of solutions into gel with 
higher viscosity was observed. 
In vitro drug release study 
The cumulative percentage release proﬁ  les of all selected 
batches obtained were compared with that of a market 
formulation [Figure 3]. In case of the marketed eye drops, 
almost all the drug was released within 60 min. On the other 
hand, all selected formulation exhibited slow release of the 
drug. Formulation coded as XP4 showed an initial high 
Figure 1: Comparative rheological proﬁ  le of the selected formulations 
at pH 5.0 and 25˚C
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burst release of the drug nearly 30%. It may be due to long 
gelation time taken by xanthan gum. Other formulations 
exhibited faster gelling and did not show burst release. The 
combination of polymers of different mechanism of in 
situ gelation with PF127 shows better improvement in in 
vitro drug release proﬁ  le than that shown by the individual 
polymers. 
The results suggest that combination of this type of 
polymers of different mechanisms of in situ gelation can 
be utilized as viscosity enhancer together with thermo-
reversible gelling polymer like PF127 in an in situ gelling 
system for ophthalmic drug delivery. The in vitro release 
of cromolyn sodium from all the formulations occurred 
primarily by diffusion. The results clearly showed that the 
formulations have an ability to retain drugs for more than 
10 h period without premature drug release. However, 
the conditions during in vitro drug release experiments 
were very different from those likely to be encountered in 
the eye. In the cul-de-sac, the formulations will probably 
undergo faster dissolution due to the shearing action of 
eyelid and eyeball movement. 
Effect of sterilization
The autoclaving exerted insigniﬁ  cant effect on the drug 
content, viscosity, and pH of the formulations [Table 2]. 
However, haziness was observed in formulations coded 
as CP9 after autoclaving due to gelation of Pluronic at 
elevated temperature. But it was found to disappear and 
the original clarity was regained after overnight storage at 
ambient conditions.
CONCLUSION
From this study, we concluded that by combining PF127 
with other in situ gelling- or viscosity-enhancing polymers 
we could not only able to reduce the concentration of 
PF127 from 25% to 15% w/v but also able to reduce 
Table 2: Effect of sterilization on selected formulations
Formulation 
Code
 Drug Content 
%w/v
 Viscosity (cps)  At 
12 rpm
  pH
Before 
stern
After 
stern
Before 
stern
After 
stern
Before 
stern
After 
stern
 CP9 98.50 98.09 887.5 887.5 4.98 4.96
 XP4 97.05 96.71 335 335 5.08 5.06
 SP8 98.41 97.58 245.5 245 5.01 5.02
 SP10 97.79 97.21 350 350 5.02 5.01
the individual polymer concentrations, i.e. carbomer and 
sodium alginate, than if they were used alone as in situ 
gelling polymers. Thus, we could reduce the side effects and 
increase the patient compliance. Such systems formulated 
with low buffer capacity and having combination of 
polymers with in situ gelation by two different mechanisms, 
can be easily transformed into gel upon instillation into 
the cul-de-sac of the dye because of rapid temperature 
change from 25 °C to 37 °C (body temperature) and rapid 
neutralization of Carbomer by pH of tear ﬂ  uid and in 
case of sodium alginate by cation Ca+2 of the tear ﬂ  uid 
of the eye.
The overall results of the study indicate that such an in 
situ gelling system is an excellent carrier for prolonged 
ophthalmic delivery of Cromolyn sodium. The gel formed 
in situ at lachrymal ﬂ  uid conditions (37 °C, 7.4 pH, Ca+2) 
exhibited sustained drug release for more than 10 h. The 
system is easy to instill into eyes because of its low viscosity 
and has an excellent ocular tolerance.
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